A patient support programme has shown that pharmacist interventions can improve adherence to diabetes medication by up to 61 per cent. The programme, which was a joint initiative by Celesio UK and MSD, was specifically designed to address patients’ individual concerns about their diabetes medication.

“We wanted to provide targeted support that was tailored to the individual needs of patients and we therefore segmented them according to their risk of non-adherence – high, medium and low – as well as their type of non-adherence – intentional versus unintentional,” says Laura Southall, service design manager for medicines adherence and patient support at Celesio.

Beliefs about a drug and the convenience of treatment or its complexity are important predictors of non-adherence. ‘Concern’ beliefs are about the adverse consequences of taking a drug, whereas ‘necessity’ beliefs are about the positive effects of a drug on someone’s health.

Previous research has found that for intentional non-adherers, ‘concerns’ play a more important role than ‘beliefs’ about the necessity of the drug for glucose lowering medications.

A total of 225 patients were recruited to the programme and were contacted via telephone and SMS text messages over a six-month period. The discontinuation rate was 8 per cent. The results show that:

• The 74 patients whose adherence was the most challenging when enrolled showed the greatest success, with average adherence increasing from 57.2 to 80.9 per cent
• Patients enrolled with low adherence ended the pilot with the highest overall adherence – up from 33.6 to 95.1 per cent (an improvement of 61.4 per cent)
• The 38 patients rated as medium adherence moved to the ‘high’ classification after an improvement of 27.7 per cent (up from 69.2 to 96.9 per cent).

“Our patient support programme has proven how effective a tailored and personalised pharmacist-led intervention can be in addressing reasons for non-adherence and driving positive outcomes,” says Laura Southall.

“Pharmacists are in an excellent position within the patient journey to make impactful interventions,” says Samuel Pygall, pharmacy strategy lead for MSD. “We are delighted to partner with Celesio on this initiative and hope that it is the beginning of collaboration that provides tailored projects that can really deliver change to healthcare provision in the community”.

Recommended

Dovonex is switched from POM to P

Dovonex Psoriasis Ointment (calcipotriol 50mcg/g) has been reclassified as a P medicine, the MHRA has announced

Pharmacists key to reducing polypharmacy in over-70s

Medication reviews by clinical pharmacists will reduce polypharmacy in the over-70s, new research suggests

Popular

Health checks and diabetes prevention New Style

This module provides an update on both the NHS Health Check and NHS diabetes prevention programmes

CPD: Anxiety disorders in adults New Style

This module will help you understand the main types of anxiety disorder and their therapeutic management

Promoting long, healthy lives - the role of pharmacy

This NPA-accredited module, developed by CIG Healthcare Partnership on behalf of Merck Consumer Health, highlights risk ...